Company Overview and News

 
Salween Azila is Majuperak's new CEO

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 1): Salween Azila Ahmad Tauffik has been appointed as new group chief executive officer (CEO) of Majuperak Holdings Bhd with immediate effect.
8141 BSMAF 1818

 
Stock With Momentum: Majuperak Holdings

2018-08-28 theedgemarkets
TRADING of the shares in Majuperak Holdings Bhd (fundamental: 0.75/3; valuation: 0.9/3) triggered our momentum algorithm yesterday for the first time this year. The group saw 1.07 million shares traded, compared with its 200-day average of 169,299 shares.
8141

 
Majuperak Holdings

2018-08-28 thestar.com.my
MAJUPERAK Holdings Bhd broke out of the uppermost 200-day simple moving average (SMA) that was exerting negative pressure on the share price on Monday. The counter has been seeing an increase in positive momentum over the last two months. The share price had been in decline since July 2017, taking it from a high of 60.5 sen to a low of 24 sen in July. The downtrend resulted in negative crossing in the SMA lines, suggesting the formation of a long-term bear market.
8141

 
Zahid’s former press secretary, three others join Utusan board

2018-07-18 theedgemarkets
KUALA LUMPUR: Datuk Ibrahim Yahaya, former press secretary to former deputy prime minister Datuk Seri Dr Ahmad Zahid Hamidi, is among the four new board members of loss-making Utusan Melayu (Malaysia) Bhd.
5754 8362 8141 BSMAF 1818

 
Zahid Hamidi's former press sec, three others join Utusan board

2018-07-17 theedgemarkets
KUALA LUMPUR (July 17): Datuk Dr Ibrahim Yahaya, former press secretary to former deputy prime minister Datuk Seri Ahmad Zahid Hamidi, is among the four new board members for loss-making Utusan Melayu (Malaysia) Bhd.
5754 8362 8141 BSMAF 1818

 
Utusan appoints Zahid’s former press sec, three others as new directors

2018-07-17 thestar.com.my
KUALA LUMPUR: Utusan Melayu (M) Bhd , the newspaper publisher owned by Umno, has appointed four new independent directors following a shake-up in its boardroom.
5754 8362 8141

 
Majuperak CEO Rustam Apandi resigns

2018-07-09 theedgemarkets
KUALA LUMPUR (July 9): Majuperak Holdings Bhd managing director and group chief executive officer Rustam Apandi Jamaludin will step down from his post on Oct 1.
8141 BSMAF 1818

 
Perak MB directs PKNP to reject Perak Corp's proposal

2018-06-28 theedgemarkets
IPOH (June 28): Menteri Besar Ahmad Faizal Azumu has reiterated his directive for the Perak State Development Corporation (PKNP) to reject Perak Corp Bhd’s (PCB) proposal on directors’ fees and remunerations.
8141 PCBB

4
Majuperak shareholders cut directors’ fees by 50%

2018-06-26 thestar.com.my
Perak Mentri Besar Ahmad Faizal Azumu(filepic) was quoted as saying that the state government had sacked seven executive officers of a GLC for excessive spending. Without naming the company, Ahmad Faizal said the dismissal would save the state RM150,000 a month.
8141 BSMAF 1818

 
Perak MB directs PKNP to reject Majuperak Holdings' proposals

2018-06-25 theedgemarkets
IPOH (June 25): Perak Menteri Besar Ahmad Faizal Azumu has directed the Perak State Development Corporation to reject all proposals which were made during the annual general meeting of Majuperak Holdings Berhad (MHB), which took place today.
8141

 
Perak MB directs state development corp to reject Majuperak’s proposals

2018-06-25 malaymail
IPOH, June 25 — Perak Mentri Besar Ahmad Faizal Azumu has directed the Perak State Development Corporation to reject all proposals which were made during the annual general meeting of Majuperak Holdings Berhad (MHB), which took place today.
8141

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...